Symbiotec Pharmalab Initial Public Offering Closes Today: Issue Subscribed 5.60x as NII Demand Surges

Symbiotec Pharmalab initial public offering closes today, Aug 27, 2026. Subscribed 5.60x by end of Day 3. NII 12.83x, employee 6.21x, retail 5.34x, QIB 0.62x.

Symbiotec Pharmalab Limited’s Rs 1,757 crore initial public offering closes today, August 27, 2026, marking the final day of a subscription window that opened on August 24. The issue saw a sharp rise in demand through Day 3 of bidding, taking the overall subscription to 5.60 times by 5:09 PM on August 26, 2026, according to the latest available subscription data.

The public issue received bids for 6,97,96,905 shares against 1,24,60,533 shares offered to investors, with the number of applications reaching 19,72,612. Non-institutional investors (NIIs) led the bidding at 12.83 times, followed by the employee category at 6.21 times and retail investors at 5.34 times. The qualified institutional buyer (QIB) portion, excluding the anchor allocation, stood at 0.62 times as of the same update.

Click Here – Get Free Investment Predictions

About Symbiotec Pharmalab

Track Symbiotec Pharmalab’s live subscription status on the Univest Screener

Symbiotec Pharmalab Limited, incorporated in 2002, operates in the pharmaceutical and biotechnology sector, developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company has built its operations around a backward-integrated manufacturing model and holds a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs as of Fiscal 2026, making it one of the few companies globally present across the top 10 such APIs.

The company’s manufacturing facilities are concentrated in Madhya Pradesh, with its Rau and Pithampur facilities approved by the US FDA, WHO-GMP, and EU-GMP. Symbiotec Pharmalab serves more than 50 domestic and 150 export customers across North America, Europe, and Asia as of March 31, 2026.

Symbiotec Pharmalab IPO: Key Details

Symbiotec Pharmalab Financial Performance

Symbiotec Pharmalab’s Total Income for FY26 was Rs 872.26 crore, up from Rs 755.98 crore in FY25 and Rs 723.33 crore in FY24. Profit After Tax for FY26 stood at Rs 109.90 crore, compared to Rs 96.79 crore in FY25 and Rs 100.06 crore in FY24. EBITDA for FY26 was Rs 231.97 crore, reflecting steady margin improvement over the past three fiscal years.

What Happens After the Issue Closes Today

With the subscription window closing today, the basis of allotment for Symbiotec Pharmalab is expected to be finalised on August 28, 2026. Successful applicants will see shares credited to their demat accounts, while refunds will be processed for unsuccessful or partially successful bids. The company’s shares are tentatively scheduled to list on the NSE and BSE on September 1, 2026.

Univest does not publish grey market premium figures. Grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified, or endorsed by SEBI, NSE, or BSE, can vary widely between trackers, and is not always accurate. Investors interested in checking informally reported premium levels may refer to independent trackers such as InvestorGain.com or Chittorgarh.com, treating this data as supplementary only.

Conclusion

Symbiotec Pharmalab’s initial public offering has closed its subscription window today with strong overall demand, led by non-institutional investors. With allotment expected on August 28 and listing tentatively scheduled for September 1, 2026, investors should track the registrar’s allotment status page for updates on their application. This article does not constitute subscription advice. Consult a SEBI-registered financial advisor before applying for any IPO.

Download the Univest iOS App or Univest Android App to track IPO allotment and listing updates.

FAQs on Symbiotec Pharmalab Initial Public Offering

What is the Symbiotec Pharmalab IPO subscription status on the final day?

Ans. By the end of Day 3 trading on August 26, 2026, Symbiotec Pharmalab’s initial public offering was subscribed 5.60 times overall, with NII demand at 12.83 times, employee subscription at 6.21 times, and retail investors at 5.34 times.

When does the Symbiotec Pharmalab IPO close?

Ans. The Symbiotec Pharmalab initial public offering closes today, August 27, 2026, marking the final day of its three-day subscription window that opened on August 24.

What does Symbiotec Pharmalab manufacture?

Ans. Symbiotec Pharmalab manufactures active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products, holding a global leadership position in corticosteroid and steroidal-hormone APIs by volume.

When will Symbiotec Pharmalab shares be allotted and listed?

Ans. The basis of allotment for Symbiotec Pharmalab is expected to be finalised on August 28, 2026, with shares tentatively scheduled to list on the NSE and BSE on September 1, 2026.

What is Symbiotec Pharmalab’s financial performance?

Ans. Symbiotec Pharmalab reported Total Income of Rs 872.26 crore and Profit After Tax of Rs 109.90 crore for FY26, up from Rs 755.98 crore and Rs 96.79 crore respectively in FY25.

Is the Symbiotec Pharmalab IPO oversubscribed?

Ans. Yes, as of the end of Day 3 (August 26, 2026), the Symbiotec Pharmalab initial public offering was subscribed 5.60 times overall, indicating the issue was oversubscribed ahead of its final day of bidding.